Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster

Wang, Xun; Jiang, Shujun; Ma, Wentai; Li, Xiangnan; Wei, Kaifeng; Xie, Faren; Zhao, Chaoyue; Zhao, Xiaoyu; Wang, Shidi; Li, Chen; Qiao, Rui; Cui, Yuchen; Chen, Yanjia; Li, Jiayan; Cai, Guonan; Liu, Changyi; Yu, Jizhen; Li, Jixi; Hu, Zixin; Zhang, Wenhong; Jiang, Shibo; Li, Mingkun; Zhang, Yanliang; Wang, Pengfei

doi:10.1016/j.chom.2023.11.012

Cited by 18 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2b), suggesting that booster vaccination with WSK-V102C is expected to be effective in protecting individuals from BA.2.87.1 infection. Interestingly, we observed distinct antibody responses in the participants of the three groups: 1) those with BA.5/BF.7 breakthrough infections 4 , 2) those with additional XBB reinfection, and 3) those vaccinated with WSK-V102C post-breakthrough infection. The XBB reinfection group showed recalled antibody responses against post-Omicron variants, but less against pre-Omicron variants like WT and Delta.…”

Section: Resultsmentioning

confidence: 81%

“…To evaluate their serum neutralization potency and breadth, we employed a panel of SARS-CoV-2 pseudoviruses (PsVs), including the wildtype (WT), B.1.617.2, BA.2, BA.5, XBB.1.5, XBB.1.16, EG.5.1, HK.3, BA.2.86, JN.1, and BA.2.87.1. Our previous study 4 revealed that individuals with BA.5/BF.7 breakthrough infections primarily had high neutralizing titers against WT, moderately reduced (∼2-fold) against Delta and early Omicron variants, but significantly lower (∼10-fold) against XBB sub-lineages and BA.2.86. Interestingly, sera from XBB reinfection displayed a shifted neutralization pattern, showing the highest geometric mean titer (GMT) of 3,343 and 2,232 against BA.5 and BA.2, respectively, i .…”

Section: Resultsmentioning

confidence: 93%

“…Neutralization assays were performed by incubating pseudoviruses with serial dilutions of monoclonal antibodies or sera, and scored by the reduction in luciferase gene expression. In brief, Vero E6 cells were seeded in a 96-well plate at a concentration of 2×10 4 cells per well. Pseudoviruses were incubated the next day with serially diluted samples tested in triplicate for 30 min at 37 °C.…”

Section: Methodsmentioning

confidence: 99%

“…The rapid and widespread transmission of SARS-CoV-2 has led to the emergence of multiple variants of concern (VOCs), most notably Omicron variant, which continues to evolve and diversify into a range of sub-lineages. Our previous research has shown that these Omicron sub-lineages, spanning BA.1 to BA.2.86, have been evolving to exhibit increased neutralization escape capabilities [1][2][3][4][5] . Since November 2023, the JN.1 variant, stemming from BA.2.86's antigenic diversity and acquiring an additional mutation (L455S) in RBD, has rapidly emerged as the dominant strain (Fig.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Robust Neutralization of SARS-CoV-2 Variants Including JN.1 and BA.2.87.1 by Trivalent XBB Vaccine-Induced Antibodies

Wang,

Jiang,

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Newly emerged SARS-CoV-2 variants like JN.1, and more recently, the hypermutated BA.2.87.1, have raised global concern. We recruited two groups of participants who had BA.5/BF.7 breakthrough infection post three doses of inactivated vaccines: one group experienced subsequent XBB reinfection, while the other received the XBB-containing trivalent WSK-V102C vaccine. Our comparative analysis of their serum neutralization activities revealed that the WSK-V102C vaccine induced stronger antibody responses against a wide range of variants, notably including JN.1 and the highly escaped BA.2.87.1. Furthermore, our investigation into specific mutations revealed that fragment deletions in NTD significantly contribute to the immune evasion of the BA.2.87.1 variant. Our findings emphasize the necessity for ongoing vaccine development and adaptation to address the dynamic nature of SARS-CoV-2 variants.

show abstract

Section: Resultsmentioning

confidence: 81%

Section: Resultsmentioning

confidence: 93%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Robust Neutralization of SARS-CoV-2 Variants Including JN.1 and BA.2.87.1 by Trivalent XBB Vaccine-Induced Antibodies

Wang,

Jiang,

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…In an immunogenicity study on SCTV01E, Wang et al reported that a booster dose of SCTV01E induced notably higher neutralizing antibodies against all tested variantsincluding WT, B.1.351, and newer strains like BA.5, BF.7, XBB.1.5-compared to breakthrough infections with BA.5/BF.7/XBB variants [48]. The SCTV01E booster group also showed elevated neutralization against diverse emerging XBB sub-lineages, such as including XBB.1.5/XBB.1.9.…”

Section: Multivalent Covid-19 Vaccinesmentioning

confidence: 99%

A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations

Qian,

Gao,

Zhang

et al. 2024

Vaccines

View full text Add to dashboard Cite

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the COVID-19 pandemic, has profoundly impacted global healthcare systems and the trajectory of economic advancement. As nations grapple with the far-reaching consequences of this unprecedented health crisis, the administration of COVID-19 vaccines has proven to be a pivotal strategy in managing this crisis. Protein-based vaccines have garnered significant attention owing to their commendable safety profile and precise immune targeting advantages. Nonetheless, the unpredictable mutations and widespread transmission of SARS-CoV-2 have posed challenges for vaccine developers and governments worldwide. Monovalent and multivalent vaccines represent two strategies in COVID-19 vaccine development, with ongoing controversy surrounding their efficacy. This review concentrates on the development of protein-based COVID-19 vaccines, specifically addressing the transition from monovalent to multivalent formulations, and synthesizes data on vaccine manufacturers, antigen composition, pivotal clinical study findings, and other features that shape their distinct profiles and overall effectiveness. Our hypothesis is that multivalent vaccine strategies for COVID-19 could offer enhanced capability with broad-spectrum protection.

show abstract

Lessons from COVID‐19: Aspects of prevention, therapeutics, and diagnostics against SARS‐CoV‐2 with special focus on JN.1 and XBB sublineages

Jaishwal,

Gyaneshwari,

Jha

et al. 2024

MedComm – Future Medicine

View full text Add to dashboard Cite

The end of second decade in the 21st century witnessed a prominent disease outbreak caused by the novel coronavirus SARS‐CoV‐2 (including most diverse omicron subvariants), where the death toll crossed the boundary of 6.9 million across the globe by December 19, 2023. All spheres of central dogma of molecular biology and host‒pathogen interaction was explored to find ways in diagnostics, isolation, curtailment, and therapy. Above all, diagnostics and therapeutics against COVID‐19 took an enormous jump, which needs to be evaluated for accuracy and feasibility and requires serious compilation for current and future generations. With the same objective, this review encompasses the diverse ways including prevention practiced and proposed during the handling of this pandemic across the globe. It involves the role of mutations in viruses and subsequent epitope mapping with potential immune escape mechanisms of SARS‐CoV‐2 variants including the conservancy of T‐cell epitopes has also been highlighted. The efficacy in antigen/antibody‐based diagnostics, RT‒PCR‐ and NGS‐based confirmation of pathogen presence, and imaging (X‐ray/CT‐scan) for symptoms and damage assessment has been thoroughly filtered. The possibility of errors in diagnostics and their cause and consequences have also been presented for the ease of readers and further improvisers.

show abstract

Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster

Cited by 18 publications

References 41 publications

Robust Neutralization of SARS-CoV-2 Variants Including JN.1 and BA.2.87.1 by Trivalent XBB Vaccine-Induced Antibodies

Robust Neutralization of SARS-CoV-2 Variants Including JN.1 and BA.2.87.1 by Trivalent XBB Vaccine-Induced Antibodies

A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations

Lessons from COVID‐19: Aspects of prevention, therapeutics, and diagnostics against SARS‐CoV‐2 with special focus on JN.1 and XBB sublineages

Contact Info

Product

Resources

About